Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of HER2-positive metastatic breast cancer.
van Ramshorst MS, Sonke GS. van Ramshorst MS, et al. N Engl J Med. 2015 May 14;372(20):1964. doi: 10.1056/NEJMc1503446. N Engl J Med. 2015. PMID: 25970057 No abstract available.
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS, van Werkhoven E, Honkoop AH, Dezentjé VO, Oving IM, Mandjes IA, Kemper I, Smorenburg CH, Stouthard JM, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG). van Ramshorst MS, et al. Among authors: van werkhoven e. Breast. 2016 Oct;29:153-9. doi: 10.1016/j.breast.2016.07.017. Epub 2016 Aug 5. Breast. 2016. PMID: 27498129 Clinical Trial.
Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.
van Ramshorst MS, van Werkhoven E, Mandjes IAM, Schot M, Wesseling J, Vrancken Peeters MTFD, Meerum Terwogt JM, Bos MEM, Oosterkamp HM, Rodenhuis S, Linn SC, Sonke GS. van Ramshorst MS, et al. Among authors: van werkhoven e. Eur J Cancer. 2017 Mar;74:47-54. doi: 10.1016/j.ejca.2016.12.023. Epub 2017 Feb 10. Eur J Cancer. 2017. PMID: 28335887 Clinical Trial.
Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.
van Ramshorst MS, Teixeira SC, Koolen BB, Pengel KE, Gilhuijs KG, Wesseling J, Rodenhuis S, Valdés Olmos RA, Rutgers EJ, Vogel WV, Sonke GS, Vrancken Peeters MT. van Ramshorst MS, et al. Cancer Imaging. 2017 May 25;17(1):15. doi: 10.1186/s40644-017-0117-5. Cancer Imaging. 2017. PMID: 28545563 Free PMC article.
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG). van Ramshorst MS, et al. Lancet Oncol. 2018 Dec;19(12):1630-1640. doi: 10.1016/S1470-2045(18)30570-9. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413379 Clinical Trial.
Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
Steenbruggen TG, van Seijen M, Janssen LM, van Ramshorst MS, van Werkhoven E, Vrancken Peeters MTDF, Wesseling J, Lips EH, Sonke GS. Steenbruggen TG, et al. Among authors: van ramshorst ms. Clin Cancer Res. 2019 Aug 15;25(16):4985-4992. doi: 10.1158/1078-0432.CCR-19-0560. Epub 2019 May 10. Clin Cancer Res. 2019. PMID: 31076546
19 results